Your Genes Shape How Medications Work
Pharmacogenomics (PGx) is the study of how an individual's genetic makeup affects their response to drugs. Genetic variants can alter how a medication is metabolized, how well it works, and its potential for toxicity. Our testing focuses on key genes, including the CYP450 family, TPMT, DPYD, and others, which are critical for predicting how patients metabolize a wide range of common medications.
Avoid Adverse Drug Reactions
Proactively identify drugs that may cause serious side effects based on your genetics.
Optimize Drug Selection and Dosing
Ensure the right medication is selected at the right dose from the start.
Improve Treatment Outcomes
Enhance therapeutic efficacy, particularly in oncology, psychiatry, and cardiology, where precise dosing is vital.
From Sample to Clinical Report
Sample Collection
A quick blood or buccal swab sample is collected — no special preparation required.
Genomic Analysis
DNA is analyzed on a comprehensive panel covering >300 variants across 29 key genes, using SNP microarray technology on the Illumina iScan™ platform.
Clinical Report
An actionable clinical report with drug-gene interaction insights is delivered, with dedicated support to interpret and apply the findings.
Genes & Drug Classes Covered
29 pharmacogenomic markers, organized into six functional categories relevant to everyday prescribing.
| Category | Key Genes | Why It Matters |
|---|---|---|
| Drug-Metabolizing Enzymes | CYP2D6 · CYP2C19 · CYP2C9 · CYP3A4 · CYP3A5 · CYP2B6 · CYP4F2 · DPYD · TPMT · NUDT15 · UGT1A · G6PD | How quickly the body activates, breaks down, or clears a wide range of medications. |
| Drug Transporters | SLCO1B1 · ABCG2 | How efficiently drugs move into and out of cells, affecting blood concentration and side-effect risk. |
| Cardiovascular & Clotting Risk | Factor V Leiden · Prothrombin (F2) · MTHFR · VKORC1 | Inherited clotting tendencies and sensitivity to blood thinners such as warfarin. |
| Oncology Markers | BRAF (V600E) · KRAS · NRAS | Tumor-pathway variants that inform eligibility for targeted cancer therapies. |
| Neuropsychiatric & Pain Response | HTR2A · COMT · GRIK4 · OPRM1 | Genetic factors linked to antidepressant response and opioid pain relief. |
| Additional Safety Markers | CFTR · CACNA1S · RYR1 · ITGB3 | Rare but serious risks, including malignant hyperthermia susceptibility and anesthesia safety. |
Cardiovascular
Oncology
Psychiatry
Pain Management
Gastroenterology
Infectious Disease
Endocrine & Rheumatology
Transplant & Immune
Recommendations You Can Trust
MolecularPGx interpretations are cross-referenced against the leading pharmacogenomic guideline bodies.
CPIC
The Clinical Pharmacogenetics Implementation Consortium publishes peer-reviewed, gene-drug prescribing guidelines.
FDA
The U.S. FDA maintains a table of pharmacogenomic biomarkers referenced in drug labeling.
DPWG
The Dutch Pharmacogenetics Working Group publishes therapeutic dose-adjustment recommendations.
Who Should Consider PGx Testing?
Poor Response to Therapy
Patients with poor response to standard therapies.
Adverse Drug Reactions
Patients experiencing adverse drug reactions.
Narrow Therapeutic Window Drugs
Individuals starting medications such as warfarin or clopidogrel.
Oncology Patients
Patients undergoing chemotherapy.
See MolecularPGx in Action
Explore a sample report and download our brochure to learn more about MolecularPGx testing.
Frequently Asked Questions
What is pharmacogenomic (PGx) testing?
PGx testing examines how an individual's genetic makeup affects their response to drugs — including how a medication is metabolized, how well it works, and its potential for toxicity.
Who should consider PGx testing?
Patients with a poor response to standard therapies, those experiencing adverse drug reactions, individuals starting medications with narrow therapeutic windows (e.g., warfarin, clopidogrel), and oncology patients undergoing chemotherapy are all good candidates.
How does the test work?
A blood or buccal swab sample is analyzed by SNP microarray on the Illumina iScan™ platform, covering a comprehensive panel across 12+ key genes. Results are compiled into a clinical report for your physician.
How can PGx affect statin therapy?
Reduced SLCO1B1 transporter function can raise statin blood levels, increasing the risk of muscle-related side effects at standard doses — guiding a lower starting dose or an alternative statin.
How can PGx affect pain management?
Variation in CYP2D6 changes how the body activates or clears opioids such as codeine and tramadol, helping guide safer, more effective pain management.
How can PGx affect clotting-risk assessment?
Markers such as Factor V Leiden help assess inherited clotting risk ahead of surgery, pregnancy, or hormone-based therapy.
What clinical guidelines does this align with?
Recommendations are cross-referenced against CPIC, FDA, and DPWG guidance — three of the leading bodies in clinical pharmacogenomics.
What sample type is required?
A quick blood draw or buccal (cheek) swab is sufficient — no special preparation is required.